Brückner O, Trautmann M, Kolodziejczyk D, Alexander M, Collmann H
J Antimicrob Chemother. 1983 Jun;11(6):565-71. doi: 10.1093/jac/11.6.565.
After administration of 150 mg netilmicin samples of CSF and blood were obtained. In one group of nine patients with no or only slight impairment of the blood-CSF-barrier 29 samples of CSF were assayed for netilmicin concentrations. All samples, obtained after the first dose, failed to reveal detectable drug levels. Drug levels up to 0.18 mg/l were detected in samples of CSF of three patients after 3 to 22 doses. Only the lumbar CSF of one patient contained netilmicin concentrations higher than 1.0 mg/l. In comparison 19 samples of CSF, obtained from patients with meningitis after more than one dose of netilmicin, had levels of 0.27-5.0 mg/l. Three CSF samples from patients out of this group, collected after the first dose of netilmicin failed to show any drug activity.
给予150毫克奈替米星后，采集了脑脊液（CSF）和血液样本。在一组9名血脑屏障无或仅有轻微损害的患者中，对29份脑脊液样本进行了奈替米星浓度检测。首次给药后采集的所有样本均未检测到可检测到的药物水平。在3至22次给药后，3名患者的脑脊液样本中检测到的药物水平高达0.18毫克/升。只有1名患者的腰段脑脊液中奈替米星浓度高于1.0毫克/升。相比之下，从接受一剂以上奈替米星治疗的脑膜炎患者中采集的19份脑脊液样本，其药物水平为0.27 - 5.0毫克/升。该组中3名患者在首次给予奈替米星后采集的脑脊液样本未显示任何药物活性。
